This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Cowen D, Richaud P, Mornex F, Bachelot T, Jung GM, Mirabel X, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 1995; 34: 9-16. doi: 10.1016/0167-8140(94)01493-mCowenDRichaudPMornexFBachelotTJungGMMirabelXet alThymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer.199534916doi10.1016/0167-8140(94)01493-mOpen DOISearch in Google Scholar
Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathology 1978; 9: 495-515. doi: 10.1016/s0046-8177(78)80131-2LevineGDRosaiJThymic hyperplasia and neoplasia: a review of current concepts.19789495515doi10.1016/s0046-8177(78)80131-2Open DOISearch in Google Scholar
Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911-9. doi: 10.1097/jto.0b013e3181a4b8e0FalksonCBBezjakADarlingGGreggRMalthanerRMaziakDEet alThe management of thymoma: a systematic review and practice guideline.200949119doi10.1097/jto.0b013e3181a4b8e0Open DOISearch in Google Scholar
Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624-32. doi: 10.1002/cncr.10226OkumuraMOhtaMTateyamaHNakagawaKMatsumuraAMaedaHet alThe World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients.20029462432doi10.1002/cncr.10226Open DOISearch in Google Scholar
Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546-51. doi: 10.1002/ijc.11099EngelsEAPfeifferRMMalignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies.200310554651doi10.1002/ijc.11099Open DOISearch in Google Scholar
Tomaszek S, Wigle DA, Keshavjee S, Fischer S. Thymomas: review of current clinical practice. Ann Thorac Surg 2009; 87: 1973-80. doi: 10.1016/j. athoracsur.2008.12.095TomaszekSWigleDAKeshavjeeSFischerSThymomas: review of current clinical practice.200987197380doi10.1016/j.athoracsur.2008.12.095Open DOISearch in Google Scholar
Chau NG, Kim ES, Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol 2010; 5: S313-7. doi: 10.1097/JTO.0b013e3181f20d9aChauNGKimESWistubaIThe multidisciplinary approach to thymoma: combining molecular and clinical approaches.20105S3137doi10.1097/JTO.0b013e3181f20d9aOpen DOISearch in Google Scholar
Miyamoto K, Acoba JD. Thymomas and thymic carcinomas: a review on pathology, presentation, staging, treatment, and novel systemic therapies. EMJ Respir 2017; 5: 100-7. doi: 10.33590/emjrespir/10310358MiyamotoKAcobaJDThymomas and thymic carcinomas: a review on pathology, presentation, staging, treatment, and novel systemic therapies.201751007doi10.33590/emjrespir/10310358Open DOISearch in Google Scholar
Peric J, Samaradzic N, Skodric Trifunovic V, Tosic N, Stojsic J, Pavlovic S, et al. Genomic profiling of thymoma using a targeted high-throughput approach. Arch Med Sci 2020. doi: 10.5114/aoms.2020.96537PericJSamaradzicNSkodricTrifunovic VTosicNStojsicJPavlovicSet alGenomic profiling of thymoma using a targeted high-throughput approach.2020doi10.5114/aoms.2020.96537Open DOISearch in Google Scholar
Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018; 122: e59. doi: 10.1002/cpmb.59SlatkoBEGardnerAFAusubelFMOverview of next-generation sequencing technologies.2018122e59doi10.1002/cpmb.59Open DOISearch in Google Scholar
Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol 2012; 25: 795-804. doi: 10.1038/modpathol.2012.29DuncavageEJAbelHJSzankasiPKelleyTWPfeiferJDTargeted next generation sequencing of clinically significant gene mutations and translocations in leukemia.201225795804doi10.1038/modpathol.2012.29Open DOISearch in Google Scholar
Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics 2014; 15: 244. doi: 10.1186/1471-2164-15-244XuHDiCarloJSatyaRVPengQWangYComparison of somatic mutation calling methods in amplicon and whole exome sequence data.201415244doi10.1186/1471-2164-15-244Open DOISearch in Google Scholar
Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017; 2017: PO.17.00011. doi: 10.1200/PO.17.00011ChakravartyDGaoJPhillipsSMKundraRZhangHWangJet alOncoKB: A Precision Oncology Knowledge Base.20172017PO.17.00011doi10.1200/PO.17.00011Open DOISearch in Google Scholar
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidem 2009; 62: e1-34. doi: 10.1016/j.jclinepi.2009.06.006LiberatiAAltmanDGTetzlaffJMulrowCGotzschePCIoannidisJPet alThe PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.200962e134doi10.1016/j.jclinepi.2009.06.006Open DOISearch in Google Scholar
Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M J, et al. A Cochrane handbook for systematic reviews of interventions. Cochrane handbook for systematic reviews of interventions. 2019. (cited 2022 Dec 19). Available at: https://training.cochrane.org/handbookHigginsJPThomasJChandlerJCumpstonMLiTPageM Jet alA Cochrane handbook for systematic reviews of interventions.2019(cited 2022 Dec 19). Available at:https://training.cochrane.org/handbookSearch in Google Scholar
Cohrain Training. RevMan 5. (accessed 2021 Aug 3). Available at: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-downloadCohrain Trainingaccessed2021Aug 3Available athttps://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-downloadSearch in Google Scholar
Girard N, Basse C, Schrock A, Ramkissoon S, Killian K, Ross JS. Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022; 27: 919-29. doi: 10.1093/oncolo/oyac115GirardNBasseCSchrockARamkissoonSKillianKRossJSComprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers.20222791929doi10.1093/oncolo/oyac115Open DOISearch in Google Scholar
Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-Wroblewska M. Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers 2022; 14: 3388. doi: 10.3390/cancers14143388SzpechcinskiASzolkowskaMWiniarskiSLechowiczUWisniewskiPKnetki-WroblewskaMTargeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas.2022143388doi10.3390/cancers14143388Open DOISearch in Google Scholar
GeneCards® The Human Gene Database. (Updated: 2023 Jan 10). Available at: https://www.genecards.org/GeneCards®Updated2023Jan 10Available athttps://www.genecards.org/Search in Google Scholar
Müllauer L. GTF2I gene mutation – a driver of thymoma pathogenesis. Mediastinum 2017; 1: 11. doi: 10.21037/med.2017.11.03MüllauerLGTF2I gene mutation – a driver of thymoma pathogenesis.2017111doi10.21037/med.2017.11.03Open DOISearch in Google Scholar
Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 2017; 110: 48-52. doi: 10.1016/j.lungcan.2017.05.02022FengYLeiYWuXHuangYRaoHZhangYet alGTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis.20171104852doi10.1016/j.lungcan.2017.05.02022Open DOISearch in Google Scholar
Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018; 33: 244-58.e10. doi: 10.1016/j.ccell.2018.01.003RadovichMPickeringCRFelauIHaGZhangHJoHet alThe integrated genomic landscape of thymic epithelial tumors.20183324458e10doi10.1016/j.ccell.2018.01.003Open DOISearch in Google Scholar
Liu D, Zhang P, Zhao J, Yang L, Wang W. Identification of molecular characteristics and new prognostic targets for thymoma by multiomics analysis. BioMed Res Int 2021; 2021: Article ID 5587441, 1-15. doi: 10.1155/2021/5587441LiuDZhangPZhaoJYangLWangWIdentification of molecular characteristics and new prognostic targets for thymoma by multiomics analysis.20212021Article ID 5587441115doi10.1155/2021/5587441Open DOISearch in Google Scholar
TCGA’s Study of Thymoma. (cited 2022 Dec 5). Available at: https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers/thymomacited2022Dec 5Available athttps://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers/thymomaSearch in Google Scholar
Venuta F, Rendina EA, Anile M, de Giacomo T, Vitolo D, Coloni GF. Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 2012; 60: 1-12. doi: 10.1007/s11748-011-0814-0VenutaFRendinaEAAnileMde GiacomoTVitoloDColoniGFThymoma and thymic carcinoma201260112doi10.1007/s11748-011-0814-0Open DOISearch in Google Scholar
Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics 2014; 46: 844-9. doi: 10.1038/ng.3016PetriniIMeltzerPSKimIKLucchiMParkKSFontaniniGet alA specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors.2014468449doi10.1038/ng.3016Open DOISearch in Google Scholar
Higuchi R, Goto T, Hirotsu Y, Yokoyama Y, Nakagomi T, Otake S, et al. Primary driver mutations in GTF2I specific to the development of thymomas. Cancers 2020; 12: 1-12. doi: 10.3390/cancers12082032HiguchiRGotoTHirotsuYYokoyamaYNakagomiTOtakeSet alPrimary driver mutations in GTF2I specific to the development of thymomas.202012112doi10.3390/cancers12082032Open DOISearch in Google Scholar
Liang NX, Liu L, Huang C, Liu HS, Guo C, Li J, et al. Transcriptomic and mutational analysis discovering distinct molecular characteristics among chinese thymic epithelial tumor patients. Front Oncol 2021; 11: 647512. doi: 10.3389/fonc.2021.647512LiangNXLiuLHuangCLiuHSGuoCLiJet alTranscriptomic and mutational analysis discovering distinct molecular characteristics among chinese thymic epithelial tumor patients.202111647512doi10.3389/fonc.2021.647512Open DOISearch in Google Scholar
Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 2019; 20: 199-210. doi: 10.1038/s41580-019-0110-xHafnerABulykMLJambhekarALahavGThe multiple mechanisms that regulate p53 activity and cell fate.201920199210doi10.1038/s41580-019-0110-xOpen DOISearch in Google Scholar
Marx A, Belharazem D, Lee DH, Popovic ZV, Reissfelder C, Schalke B, et al. Molecular pathology of thymomas: implications for diagnosis and therapy. Virchows Arch 2021; 478: 101-10. doi: 10.1007/s00428-021-03068-8MarxABelharazemDLeeDHPopovicZVReissfelderCSchalkeBet alMolecular pathology of thymomas: implications for diagnosis and therapy.202147810110doi10.1007/s00428-021-03068-8Open DOISearch in Google Scholar
Chen K, Che JM, Zhang XF, Jin RS, Xiang J, Han DP, et al. Next-generation sequencing in thymic epithelial tumors uncovered novel genomic aberration sites and strong correlation between TMB and MSH6 single nucleotide variations. Cancer Letters 2020; 476: 75-86. doi: 10.1016/j.canlet.2020.02.001ChenKCheJMZhangXFJinRSXiangJHanDPet alNext-generation sequencing in thymic epithelial tumors uncovered novel genomic aberration sites and strong correlation between TMB and MSH6 single nucleotide variations.20204767586doi10.1016/j.canlet.2020.02.001Open DOISearch in Google Scholar
Xu S, Li XF, Zhang HY, Zu LL, Yang LQ, Shi T, et al. Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors. Front Oncol 2021; 11: 667148. doi: 10.3389/fonc.2021.667148XuSLiXFZhangHYZuLLYangLQShiTet alFrequent genetic alterations and their clinical significance in patients with thymic epithelial tumors.202111667148doi10.3389/fonc.2021.667148Open DOISearch in Google Scholar
Jovanovic D, Markovic J, Ceriman V, Peric J, Pavlovic S, Soldatovic I. Correlation of genomic alterations and PD-L1 expression in thymoma. J Thorac Dis 2020; 12: 7561-70. doi: 10.21037/jtd-2019-thym-13JovanovicDMarkovicJCerimanVPericJPavlovicSSoldatovicICorrelation of genomic alterations and PD-L1 expression in thymoma.202012756170doi10.21037/jtd-2019-thym-13Open DOISearch in Google Scholar
Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res 2017; 23: 551-64. doi: 10.1007/s12253-016-0144-8EnknerFPichlhöferBZaharieATKrunicMHolperTMJanikSet alMolecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets.20172355164doi10.1007/s12253-016-0144-8Open DOISearch in Google Scholar
Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 2014; 9: S131-S6. doi: 10.1097/JTO.0000000000000298RajanAGirardNMarxAState of the art of genetic alterations in thymic epithelial tumors.20149S131S6doi10.1097/JTO.0000000000000298Open DOISearch in Google Scholar
Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, et al. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 2019; 75: 755-66. doi: 10.1111/his.13936SakaneTMuraseTOkudaKSaidaKMasakiAYamadaTet alA mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3.20197575566doi10.1111/his.13936Open DOISearch in Google Scholar